IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting

INTRODUCTION: Treatment with IDegLira has the potential to improve glycemic control in patients with type 2 diabetes mellitus (T2DM) without the weight gain and with a lower risk of hypoglycemia than with other therapies. The aim of the present analysis was to evaluate the long-term cost-effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Barnaby, Mocarski, Michelle, Valentine, William J., Langer, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446378/
https://www.ncbi.nlm.nih.gov/pubmed/28349444
http://dx.doi.org/10.1007/s13300-017-0251-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446378/
https://www.ncbi.nlm.nih.gov/pubmed/28349444
http://dx.doi.org/10.1007/s13300-017-0251-x

Ejemplares similares